Osimertinib for Uncommon Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Carcinoma: A Case Report
Background: Non-small cell lung cancer (NSCLC) accounts for 84% of all lung cancers and continues to remain the leading cause of cancer-related mortality worldwide. The advent of gene targeted therapies has changed the landscape of NSCLC management. Osimertinib is a third-generation tyros...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-11-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000542201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|